Clinical Trials on Mild Alzheimer's Disease in New Zealand

Total 43932 results

Cognito Therapeutics, Inc.

Active, not recruiting

Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture)

Cognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Dementia, Alzheimer Type | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, Mild

United States
Cognito Therapeutics, Inc.

Enrolling by invitation

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia Moderate

United States
NeuroActiva, Inc.

Completed

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Neurocognitive Disorders | Neurodegenerative Diseases | Cognitive Impairment | Alzheimer Disease | Tauopathies | Mild Cognitive Impairment | Dementia, Vascular | Dementia With Lewy Bodies | Alzheimer Dementia | Cognitive Disorder

New Zealand
Cognito Therapeutics, Inc.

Recruiting

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011) (Hope)

Cognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditions

United States
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
Neuroscience Trials Australia
The Florey Institute of Neuroscience and Mental Health

Active, not recruiting

Deferiprone to Delay Dementia (The 3D Study)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's Disease

Australia
CuraSen Therapeutics, Inc.

Completed

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

Dementia | Mild Cognitive Impairment

United States, New Zealand
AstraZeneca

Completed

A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

Mild Cognitive Impairment | Mild Alzheimer's Disease

United States
Oryzon Genomics S.A.
Alzheimer's Drug Discovery Foundation

Completed

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease (ETHERAL-US)

Mild to Moderate Alzheimer's Disease

United States
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
Eisai Inc.
Pfizer

Completed

The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility

Mild to Severe Alzheimer's Disease

United States
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Completed

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD) | Significant Memory Concern (SMC) | Early Mild Cognitive Impairment (EMCI) | Late Mild Cognitive Impairment (LMCI)

United States, Canada
Atridia Pty Ltd.

Not yet recruiting

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease (AD)

Australia
NYU Langone Health
Alzheimer's Association

Recruiting

Innate Immunity Stimulation Via TLR9 in Early AD

Mild Cognitive Impairment | Alzheimer Dementia

United States
Takeda

Terminated

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Australia, United Kingdom, Switzerland
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) (ADNI3)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD)

United States, Canada
Sage Therapeutics

Active, not recruiting

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease | Mild Dementia

United States, Puerto Rico
Alkahest, Inc.

Completed

A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease | Mild to Moderate Alzheimer Disease

United States
University of Southern California
National Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Wake Forest University Health Sciences

Completed

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment

United States
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Completed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, France, Spain, Ireland, Australia, Puerto Rico, United Kingdom
Zealand University Hospital
University of Copenhagen; Technical University of Denmark; OptoCeutics

Completed

Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System (ALZLIGHT Pilot)

Alzheimer Disease

Denmark
Icahn School of Medicine at Mount Sinai

Recruiting

Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Weill Medical College of Cornell University

Active, not recruiting

The Comparative Effectiveness Dementia & Alzheimer's Registry (CEDAR)

Alzheimer Disease | Mild Cognitive Impairment

United States
Icahn School of Medicine at Mount Sinai
National Institute on Aging (NIA)

Recruiting

7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

Mild Cognitive Impairment | Alzheimer's Disease

United States
Weill Medical College of Cornell University
National Institute on Aging (NIA)

Completed

PET Measures of CSF Clearance in Preclinical Alzheimer's Disease

Mild Cognitive Impairment

United States
NYU Langone Health

Terminated

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

Alzheimer Disease

United States
Icahn School of Medicine at Mount Sinai

Recruiting

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

Mild Cognitive Impairment

United States
Icahn School of Medicine at Mount Sinai
National Institute on Aging (NIA); Rutgers University

Recruiting

The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment

Mild Cognitive Impairment | Alzheimer's Disease

United States
The Mind Research Network

Completed

Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease (MEMORI)

Alzheimer Disease | Mild Cognitive Impairment

United States
Icahn School of Medicine at Mount Sinai

Active, not recruiting

Rhythmic Light Therapy for Alzheimer's Disease Patients

Mild Cognitive Impairment

United States
Icahn School of Medicine at Mount Sinai

Recruiting

A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1

Mild Cognitive Impairment | Alzheimer's Disease

United States
Icahn School of Medicine at Mount Sinai

Active, not recruiting

Understanding Circadian Responses to Light in Persons With Mild Cognitive Impairment

Alzheimer Disease | Mild Cognitive Impairment

United States
NYU Langone Health
National Institutes of Health (NIH); Alzheimer's Association; LiteCure LLC

Recruiting

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Alzheimer Disease | Mild Cognitive Impairment

United States
AgeneBio
National Institute on Aging (NIA)

Completed

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (HOPE4MCI)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease

United States, Canada
Taipei Medical University Shuang Ho Hospital

Completed

The Effects of Intermittent Theta Burst Stimulation in MCI and Early AD

Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline

Taiwan
iPACES LLC
Albany Medical College; 1st Playable Productions; Pacific Brain Health Center; Adirondack...

Recruiting

The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI) (iPACES)

Dementia | Alzheimer Disease | Mild Cognitive Impairment | MCI

United States
Union College, New York
US Department of Veterans Affairs

Completed

Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults

Dementia | Mild Cognitive Impairment | Cognitive Decline | Alzheimer's Disease

United States
Weill Medical College of Cornell University
National Institute on Aging (NIA); Tolmar Pharmaceuticals

Recruiting

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (LUCINDA)

Alzheimer Disease | Mild Cognitive Impairment

United States
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, France, Ireland, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom, Brazil, Japan, Germany
Washington University School of Medicine
National Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Alzheimers Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

Alzheimers Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

Alzheimers Disease

United States
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase (CT04 POLEP)

Alzheimer's Disease

United States, Italy
Actinogen Medical
Avance Clinical

Completed

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers (XanaMIA-DR)

Mild Cognitive Impairment | Alzheimer's Disease

Australia
Actinogen Medical

Recruiting

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease (XanaMIA)

Alzheimer Disease | Dementia, Mild | Dementia Moderate

Australia
Eisai Inc.
Biogen

Terminated

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Alzheimer Disease | Dementia, Alzheimer Type

United States
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)

Alzheimer's Disease

United States, Italy
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States

Clinical Trials on Mild Alzheimer's Disease in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations